Caring for people with learning disabilities and dementia: pharmacotherapeutic considerations.
Why you should read this article: • To enhance your understanding of dementia in people with learning disabilities, including the increased risk of early-onset Alzheimer's disease in people with Down's syndrome • To recognise pharmacological treatments used for the management of dementia and the imp...
| Publicado en: | Learning Disability Practice Vol. 29; no. 1; pp. 16 - 24 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Royal College of Nursing of the United Kingdom (The)
Feb2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191492662&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191492662 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14658712 FTU jtl: Learning Disability Practice issn: 14658712 maglogo: N pubinfo: dt: Feb2026 vid: 29 iid: 1 pid: 6040 pub: Royal College of Nursing of the United Kingdom (The) artinfo: ui: 191492662 191492662 191492662 10.7748/ldp.2025.e2270 191492662 ppf: 16 ppct: 8 formats: tig: atl: Caring for people with learning disabilities and dementia: pharmacotherapeutic considerations. aug: au: Harper, Lynette Mackay, Sarah affil: Assistant professor, Northumbria University, Newcastle upon Tyne, England sug: subj: Dementia Drug Therapy Learning Disorders Drug Therapy Donepezil Therapeutic Use Donepezil Adverse Effects Down Syndrome Alzheimer's Disease Risk Factors Risk Assessment Cues Aging Comorbidity Polypharmacy Dementia Nursing Nursing Care Rivastigmine Therapeutic Use Rivastigmine Adverse Effects Memantine Therapeutic Use Memantine Adverse Effects ab: Why you should read this article: • To enhance your understanding of dementia in people with learning disabilities, including the increased risk of early-onset Alzheimer's disease in people with Down's syndrome • To recognise pharmacological treatments used for the management of dementia and the importance of medicine dose adjustments and monitoring of side effects in people with learning disabilities • To stay informed about new and emerging dementia medicines. People with learning disabilities, particularly those with Down's syndrome, are at increased risk of developing dementia, often at a younger age than the general population. Although there is no cure for dementia, treatment can include dementia medicines that aim to alleviate the associated symptoms and delay progression of the disease. The dementia medicine selected depends on the type and stage of the condition, contraindications and potential drug interactions with those prescribed for comorbid health conditions. This article provides an overview of dementia in people with learning disabilities and explores the use of dementia medicines in this population, including the implications of comorbidities and polypharmacy in terms of dose titration and risk of side effects. The authors also discuss new and emerging dementia medicines. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|